ClinicalTrials.gg
Enrolling by invitationNCT06113588Updated Nov 2, 2023

Transition of Care in Type 1 Diabetes Mellitus

An observational study in Transition and Type 1 Diabetes Mellitus, sponsored by Northern Sydney and Central Coast Area Health Service. Enrolling by invitation at 1 site in Australia. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Northern Sydney and Central Coast Area Health Service · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
80
Ages
16 Years and older
Sex
All
01

Study summary

This research project seeks to address the question of how to improve the transition of patients with type 1 diabetes mellitus from the paediatric to the adult health service at RNSH and Mona Vale Community Health Centre (seeking the perspectives of patients, families, and staff)?

Read the detailed description

There are significant limitations in the literature relating to transition from paediatric to adult healthcare.

In healthcare, transition describes the purposeful process of planning and moving from paediatric to adult services and usually occurs in adolescence (in itself a time of rapid physical, cognitive and psychosocial growth between childhood and adulthood). The available evidence within the literature to guide this process of transition is often limited and additional evidence to guide clinical practice is required. Although reports within the literature vary, it is known that up to 50% of young adults with an endocrine disorder are lost to follow-up after transition to adult health services. Even if the young person attends the adult service, they may have poor health outcomes related to inability to self-manage their condition, particularly if it is a chronic disease requiring significant daily intervention by the patient, such as in type 1 diabetes mellitus.

Type 1 diabetes mellitus is a life-long condition characterised by autoimmune-mediated destruction of pancreatic β-cells, almost always resulting in absolute insulin deficiency. As a result, patients are required to perform lifelong intensive glucose monitoring and insulin administration. These intensive insulin regimens require an enormous amount of attention and effort on the part of the young person with diabetes and their family, but dramatically reduce their rates of micro- and macro-vascular complications, such as blindness, kidney failure, heart attack and stroke. Evidence for this 'legacy effect' - the long-term clinical benefits of early intensive insulin treatment - are provided through studies including the EDIC (Epidemiology of Diabetes Interventions and Complications) study which undertook long-term follow up of the Diabetes Control and Complications Trial (DCCT). The DCCT, conducted from 1983-1989, randomised 1441 participants with new or recently-diagnosed type 1 diabetes to receive either intensive insulin therapy or standard therapy. The DCCT/EDIC study ultimately recommended maintaining patients' glucose levels as close to the normal range as safely possible, with intensive insulin therapy and monitoring.

Glycaemic control and transition in adolescents with type 1 diabetes mellitus has its own specific challenges. Across all age groups, adolescents are currently the farthest from achieving good glycaemic control (a HbA1c goal of \<58 mmol/mol or 7.0%). The factors contributing to this may include hormonal changes during puberty, psycho-social challenges and decreased adherence to insulin therapy regimens.

Appropriate transition of patients with type 1 diabetes from paediatric to adult health care thus needs to take a holistic approach to the individual patient which addresses these factors and which is centred on individual patients' developmental stages and circumstances.

The local transition process at Royal North Shore Hospital has future potential At Royal North Shore Hospital, there is a structured transition process underpinned by the transition policy. However, initial analysis indicates that patients are missing appointments and education, and being lost to follow-up. There is accordingly a pressing need for analysis of the transition process and its outcomes.

Within the current literature, evaluation measures to assess patients' diabetes self-management and transition readiness (including glucose monitoring, insulin and food regulation, exercise, and emergency preparedness) frequently rely on patient self-report and emphasise knowledge and practical skills in diabetes care.

This research will provide additional insights from the patient's family and from treating staff as well as explore self-efficacy (the individual's belief in their capacity to execute behaviours) which are often poorly studied in transition research. It is anticipated that this will provide a comprehensive picture of areas in which patients' efficacy, transition readiness, knowledge and diabetes-related distress can have tailored support provided in an individualised way.

This research project will utilise the following questionnaires, with access for all participants via a QR code using Northern Sydney Local Health District (NSLHD) REDCap (a secure, web-based application for building and managing online surveys and databases).

  1. A modified READDY tool assessing transition readiness and self-efficacy - with versions that can be answered separately by the patient, the patient's family member, and the patient's healthcare professional.
  2. Diabetes knowledge questionnaire - with versions that can be answered separately by the patient and patient's family member
  3. Diabetes distress questionnaire - with versions that can be answered separately by the patient and the patient's family member
  4. Evaluation of the transition process - with versions that can be answered separately by patient, patient's family member and staff member
02

Conditions studied

  • Transition
  • Type 1 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 1

3,614 studies on the registry are indexed under Diabetes Mellitus, Type 1; 586 are open to participants now.

This study's planned enrollment of 80 is below the median of 121 across 769 observational studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Northern Sydney and Central Coast Area Health Service is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with type 1 diabetes mellitus meeting inclusion criteria, above

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adolescents who have an existing diagnosis of type 1 diabetes mellitus and who underwent (in 2020 to 8th June, 2023) or who are undergoing (from 9th June, 2023 and subsequent cohorts) transition from paediatric care to adult health care at Royal North Shore Hospital and Mona Vale Community Health Centre. Adolescents with type 1 diabetes will be 16 years or older

A family member or caregiver of the participant of the adolescent patient with type 1 diabetes mellitus

A staff member who is a member of the patient's treating diabetes team within the paediatric diabetes service (first study visit and second study visit) and young adult diabetes service (third study visit)

Exclusion criteria

Exclusion Criteria:

There are no specific exclusion criteria

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cohort

    Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, who underwent transition from paediatric to adult health care from 1st January 2020-8th June 2023

  • Prospective cohort

    Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, undergoing transition from paediatric to adult health care, from 9th June 2023 onwards

06

What researchers measure

Primary outcomes

  1. Patient self-efficacy (patient, family and staff member) relating to diabetes

    From prospective questionnaires, with higher scores indicative of higher self-efficacy

    Time frame: From 9th June, 2023, ongoing for initial period of 5 years with interim sequential reviews

  2. Diabetes knowledge questionnaire (patient and family member)

    From prospective questionnaires, with a single correct answer per question

    Time frame: From 9th June, 2023, ongoing for initial period of 5 years with interim sequential reviews

  3. Diabetes-related distress (patient and family member)

    From prospective questionnaires, with higher scores indicative of higher distress levels

    Time frame: From 9th June, 2023, ongoing for initial period of 5 years with interim sequential reviews

Secondary outcomes

  1. Patient medical outcomes

    HbA1c (%) over time

    Time frame: From 9th June, 2023, ongoing for initial period of up to 5 years with interim sequential reviews

  2. Patient medical outcomes

    Frequency (number) of emergency department presentations

    Time frame: From 9th June, 2023, ongoing for initial period of up to 5 years with interim sequential reviews

  3. Patient medical outcomes

    Percentage of patients developing diabetes complications

    Time frame: From 9th June, 2023, ongoing for initial period of up to 5 years with interim sequential reviews

07

Study locations

1 site
  • Royal North Shore Hospital
    Sydney, New South Wales 2065, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2024, 12 months after the start.

Of 239 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 12 months is below that.

Counting every sponsor, half of 288 studies reached it within 27 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Nov 2, 2023
StartActual
Jun 9, 2023
Primary completionEst.
Jun 9, 2024
CompletionEst.
Jun 9, 2028
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06113588
Lead sponsor
Northern Sydney and Central Coast Area Health Service
Responsible party
Shihab Hameed (Principal Investigator, Northern Sydney and Central Coast Area Health Service) — Principal investigator
First posted
Nov 2, 2023
Start date
Jun 9, 2023
Primary completion
Jun 9, 2024 (estimated)
Completion
Jun 9, 2028 (estimated)
Last update
Nov 2, 2023

Study contacts

Shihab Hameed, MBBS
principal investigator · Royal North Shore Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion